`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF MASSACHUSETTS
`
`TEVA PHARMACEUTICALS
`INTERNATIONAL GMBH and
`TEVA PHARMACEUTICALS USA, INC.,
`
`Plaintiffs,
`
`v.
`
`ELI LILLY AND COMPANY,
`
`Defendant.
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`Case No. 1:18-cv-12029-ADB
`
`DEFENDANT ELI LILLY AND COMPANY’S MOTION IN LIMINE NO. 1
`REGARDING JUDICIAL ESTOPPEL
`
`Pursuant to Local Rule 7.1, Defendant Eli Lilly and Company (“Lilly”) respectfully moves
`
`(1) to preclude Plaintiffs Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals
`
`USA, Inc. (“Teva”) under the doctrine of judicial estoppel from introducing arguments, evidence,
`
`or testimony contradicting positions it prevailed on when defending the patents-in-suit during
`
`related IPR proceedings; and (2) to hold these positions as established facts for purposes of this
`
`case. The grounds for the motion are fully set forth in Lilly’s memorandum in support of this
`
`motion, and the declaration of Marta Garcia Daneshvar in support of Lilly’s motion with
`
`accompanying exhibits, filed concurrently with this motion.
`
`REQUEST FOR ORAL ARGUMENT
`
`Pursuant to Local Rule 7.1(d), Lilly requests oral argument on this motion.
`
`1
`
`
`
`Case 1:18-cv-12029-ADB Document 472 Filed 09/16/22 Page 2 of 3
`
`Dated: September 16, 2022
`
`William B. Raich
`Danielle A. Duszczyszyn
`Denise Main
`Pier D. DeRoo
`Matthew Luneack
`Yoonjin Lee
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`William.Raich@finnegan.com
`Danielle.Duszczyszyn@finnegan.com
`Denise.Main@finnegan.com
`Pier.DeRoo@finnegan.com
`Matthew.Luneack@finnegan.com
`Yoonjin.Lee@finnegan.com
`
` /s/ Andrea L. Martin
`Andrea L. Martin (BBO 666117)
`BURNS & LEVINSON LLP
`125 High Street
`Boston, MA 02110-1624
`(617) 345-3000
`amartin@burnslev.com
`
`Charles E. Lipsey
`Ryan O’Quinn
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`1875 Explorer Street
`Suite 800
`Reston, VA 20190-6023
`Charles.Lipsey@finnegan.com
`Oquinnr@finnegan.com
`
`Emily R. Gabranski (BBO 694417)
`Marta Garcia Daneshvar
`Lulu Wang (BBO 704042)
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`2 Seaport Lane
`Boston, MA 02210-2001
`Emily.Gabranski@finnegan.com
`Marta.Garcia@finnegan.com
`Lulu.Wang@finnegan.com
`
`Attorneys for Defendant
`Eli Lilly and Company
`
`2
`
`
`
`Case 1:18-cv-12029-ADB Document 472 Filed 09/16/22 Page 3 of 3
`
`LOCAL RULE 7.1 CERTIFICATION
`
`I hereby certify that, pursuant to Local Rule 7.1, counsel for Lilly conferred with counsel
`for Teva and attempted in good faith to resolve or narrow the issues presented in this motion. The
`parties conferred via telephone at least on August 17, 2022 and by email at least on August 19 and
`23, 2022. Teva opposes this motion.
`
`/s/Andrea L. Martin
`Andrea L. Martin, Esq.
`
`CERTIFICATE OF SERVICE
`
`I, Andrea L. Martin, hereby certify that this document filed through the ECF system will be sent
`electronically to the registered participants as identified on the Notice of Electronic Filing
`(NEF) and paper copies will be sent to those indicated as non-registered participants on September
`16, 2022.
`
`/s/Andrea L. Martin
`Andrea L. Martin, Esq.
`
`3
`
`